Published in Lancet on October 06, 2001
Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther (2013) 3.29
Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation (2010) 2.85
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J (2009) 2.63
Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol (2009) 2.57
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis (2006) 2.28
N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int (2007) 2.03
Dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase. Circulation (2012) 1.94
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2005) 1.73
Sex and haemodynamics in pulmonary arterial hypertension. Eur Respir J (2013) 1.61
Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr (2008) 1.57
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol (2007) 1.52
Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol (2005) 1.47
Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest (2014) 1.44
Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates. Ann Thorac Med (2014) 1.40
Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart (2012) 1.39
Therapeutic effect of prostaglandin E1 in monocrotaline-induced pulmonary arterial hypertension rats. Anat Cell Biol (2017) 1.38
The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol (2007) 1.38
Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J (2011) 1.36
Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol (2005) 1.29
Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis (2007) 1.27
Response to bosentan in children with pulmonary hypertension. Heart (2005) 1.26
Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart (2005) 1.26
Pulmonary arterial hypertension: an update. Neth Heart J (2011) 1.26
Cell signaling by protein carbonylation and decarbonylation. Antioxid Redox Signal (2010) 1.21
A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis (2004) 1.20
Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic Biol Med (2012) 1.19
Can we improve outcome of congenital diaphragmatic hernia? Pediatr Surg Int (2009) 1.19
Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol (2010) 1.18
Pulmonary arterial hypertension. Orphanet J Rare Dis (2013) 1.18
Pulmonary hypertension: diagnosis and management. Mayo Clin Proc (2009) 1.18
Pulmonary arterial hypertension: the clinical syndrome. Circ Res (2014) 1.11
Endothelin. Cell Mol Life Sci (2010) 1.10
Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag (2007) 1.09
Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. Angiogenesis (2010) 1.09
Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J (2010) 1.06
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis (2006) 1.05
Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer. Br J Pharmacol (2013) 1.03
How valid are animal models to evaluate treatments for pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol (2006) 1.03
High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4. Mol Med (2013) 1.02
The cardiovascular physiology and pharmacology of endothelin-1. Adv Pharmacol (2010) 1.01
A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Mol Cancer (2010) 1.00
Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: complex congenital cardiac lesions. Can J Cardiol (2010) 1.00
Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag (2006) 0.99
Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol (2009) 0.98
Acute right ventricular failure in the setting of acute pulmonary embolism or chronic pulmonary hypertension: a detailed review of the pathophysiology, diagnosis, and management. Curr Cardiol Rev (2008) 0.98
Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart (2006) 0.97
Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology (Oxford) (2003) 0.97
Giant, dissecting, high-pressure pulmonary artery aneurysm: case report of a 1-year natural course. Tex Heart Inst J (2005) 0.97
Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res (2010) 0.97
RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension. Vasc Health Risk Manag (2009) 0.96
Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis (2007) 0.95
Gene expression of endothelin-1 and endothelin receptor a on monocrotaline-induced pulmonary hypertension in rats after bosentan treatment. Korean Circ J (2010) 0.94
Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. Vasc Health Risk Manag (2009) 0.94
Vascular involvement in systemic sclerosis (scleroderma). J Inflamm Res (2011) 0.93
Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension. Free Radic Biol Med (2012) 0.93
Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy. Clin Chest Med (2007) 0.93
Cavitating lung lesions in chronic thromboembolic pulmonary hypertension. J Radiol Case Rep (2008) 0.93
Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 0.93
Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease. Womens Health (Lond Engl) (2010) 0.92
Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia (2014) 0.91
Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol (2007) 0.91
Gene expressions of nitric oxide synthase and matrix metalloproteinase-2 in monocrotaline-induced pulmonary hypertension in rats after bosentan treatment. Korean Circ J (2011) 0.91
Lung involvement in systemic sclerosis. Presse Med (2010) 0.90
A review of pulmonary arterial hypertension: role of ambrisentan. Vasc Health Risk Manag (2007) 0.90
Endothelin-receptor antagonists in pulmonary hypertension. Lancet (2001) 0.90
Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan. Ther Clin Risk Manag (2010) 0.89
Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis (2007) 0.89
The role of endothelin-1 in pulmonary arterial hypertension. Glob Cardiol Sci Pract (2014) 0.89
Overview of current therapeutic approaches for pulmonary hypertension. Pulm Circ (2011) 0.89
Reducing TRPC1 Expression through Liposome-Mediated siRNA Delivery Markedly Attenuates Hypoxia-Induced Pulmonary Arterial Hypertension in a Murine Model. Stem Cells Int (2014) 0.87
NOS2 polymorphisms associated with the susceptibility to pulmonary arterial hypertension with systemic sclerosis: contribution to the transcriptional activity. Arthritis Res Ther (2006) 0.87
Endothelins and their inhibition in the human skin microcirculation: ET[1-31], a new vasoconstrictor peptide. Br J Clin Pharmacol (2004) 0.87
New perspectives for the treatment of pulmonary hypertension. Br J Pharmacol (2011) 0.87
Diagnosis and management of pulmonary arterial hypertension. Pulm Med (2011) 0.87
Using bosentan to treat paraquat poisoning-induced acute lung injury in rats. PLoS One (2013) 0.87
Right ventricular plasticity and functional imaging. Pulm Circ (2012) 0.87
Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol (2002) 0.86
Asymptomatic pulmonary hypertension in systemic lupus erythematosus. Clin Med Insights Arthritis Musculoskelet Disord (2011) 0.86
Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin (2012) 0.86
Treatment of pulmonary hypertension. BMJ (2003) 0.85
Current challenges in pediatric pulmonary hypertension. Semin Respir Crit Care Med (2013) 0.85
Bosentan, an endothelin receptor antagonist, reduces leucocyte adhesion and inflammation in a murine model of inflammatory bowel disease. Int J Colorectal Dis (2005) 0.85
C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target. Curr Pharm Des (2010) 0.85
Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc Health Risk Manag (2009) 0.85
Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension. Pulm Circ (2013) 0.85
Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart (2007) 0.85
Clinical trials in systemic sclerosis: lessons learned and outcomes. Arthritis Res Ther (2007) 0.84
Are hemodynamics surrogate end points in pulmonary arterial hypertension? Circulation (2014) 0.83
Long term survival in primary pulmonary hypertension. Heart (2004) 0.83
Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Tex Heart Inst J (2005) 0.83
Beneficial and adverse effects of bosentan treatment in korean patients with pulmonary artery hypertension. Korean Circ J (2009) 0.83
Endothelin antagonists in hypertension and kidney disease. Pediatr Nephrol (2012) 0.82
Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course. Ther Clin Risk Manag (2014) 0.82
Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies. Biomed Res Int (2014) 0.82
Reliance on end-expiratory wedge pressure leads to misclassification of pulmonary hypertension. Eur Respir J (2014) 0.82
Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med (1996) 11.76
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med (1996) 8.02
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med (1998) 7.08
Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med (1995) 6.97
Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J (2009) 6.64
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet (2008) 5.01
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med (1996) 4.10
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med (2000) 4.07
Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol (1994) 3.83
Chronic thromboembolic pulmonary hypertension. N Engl J Med (2001) 3.51
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum (2004) 3.46
Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence. JAMA (1997) 3.35
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med (2001) 3.29
Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J (2010) 2.90
Results of single-lung transplantation for bilateral pulmonary fibrosis. The Toronto Lung Transplant Group. N Engl J Med (1990) 2.85
Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J (2005) 2.83
Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J (2005) 2.82
Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med (1995) 2.76
Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med (1994) 2.75
SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum (1999) 2.70
Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest (2000) 2.64
Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest (2001) 2.59
Primary pulmonary hypertension. Lancet (1998) 2.47
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J (2009) 2.41
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J (2006) 2.39
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
Upregulated TRP and enhanced capacitative Ca(2+) entry in human pulmonary artery myocytes during proliferation. Am J Physiol Heart Circ Physiol (2001) 2.35
The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis (2003) 2.34
Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest (1997) 2.29
Primary pulmonary hypertension. Chest (1993) 2.26
Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med (2000) 2.25
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J (1998) 2.14
Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation (1997) 2.03
Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax (2005) 2.03
Primary pulmonary hypertension and fenfluramine use. Br Heart J (1993) 2.02
Isolation and characterization of the inositol cyclic phosphate products of polyphosphoinositide cleavage by phospholipase C. Physiological effects in permeabilized platelets and Limulus photoreceptor cells. J Biol Chem (1985) 1.98
myo-Inositol polyphosphate may be a messenger for visual excitation in Limulus photoreceptors. Nature (1984) 1.96
Capacitative Ca(2+) entry in agonist-induced pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol (2001) 1.94
Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation (1982) 1.92
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer (2012) 1.90
Increased plasma serotonin in primary pulmonary hypertension. Am J Med (1995) 1.86
Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J (2009) 1.85
Spinal fractures in patients with ankylosing spondylitis. Eur Spine J (1996) 1.83
Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation (1998) 1.80
Pulmonary veno-occlusive disease: a case series and new observations. Chest (2000) 1.80
The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society. Am J Respir Crit Care Med (1999) 1.80
Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J (2006) 1.78
Oral hydralazine therapy for primary pulmonary hypertension. N Engl J Med (1980) 1.77
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet (2003) 1.76
[Guidelines for the diagnosis and treatment of pulmonary hypertension]. Rev Mal Respir (2010) 1.74
Chronic thromboembolic pulmonary hypertension. Eur Respir J (2004) 1.74
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J (2004) 1.73
High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest (1999) 1.70
Ectopic breast cancer: case report and literature review. Surg Oncol (1994) 1.70
Hypoxia reduces potassium currents in cultured rat pulmonary but not mesenteric arterial myocytes. Am J Physiol (1993) 1.67
Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med (2002) 1.65
Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension. J Am Coll Cardiol (2001) 1.65
Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. J Thromb Haemost (2003) 1.64
Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med (2006) 1.63
The use of combination therapy in pulmonary arterial hypertension: new developments. Eur Respir Rev (2009) 1.60
Distinctive clinical features of portopulmonary hypertension. Chest (1997) 1.59
Observation and execution of movement: similarities demonstrated by quantified electroencephalography. Eur J Neurosci (1999) 1.57
Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur Respir J (2000) 1.54
Thrombotic risk factors in pulmonary hypertension. Eur Respir J (2000) 1.54
Double lung transplantation in situs inversus with Kartagener's syndrome. Paris-Sud University Lung Transplant Group. J Thorac Cardiovasc Surg (1994) 1.53
Community respiratory viral infection in adult lung transplant recipients. Chest (1998) 1.53
Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet (1998) 1.51
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J (2007) 1.51
Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med (2000) 1.51
Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J (1998) 1.51
Rodent models of depression: forced swimming and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci (2001) 1.51
Hypoxia inhibits gene expression of voltage-gated K+ channel alpha subunits in pulmonary artery smooth muscle cells. J Clin Invest (1997) 1.51